Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Launched by VITROLIFE · Sep 6, 2013
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Objective: To study whether a culture medium that allows undisturbed culture supports human embryo development to the blastocyst stage equivalently to a well-established sequential media.
Design: Randomized, double-blinded sibling trial. Setting: Independent in vitro fertilization (IVF) clinics. Patient(s): One hundred twenty-eight patients, with 1,356 zygotes randomized into two study arms.
Intervention(s): Embryos from each patient were randomly allocated into two study arms to compare embryo development on a time-lapse system using a single-step medium or sequential media.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 6 or more normal embryos following egg retrieval and fertilization.
- • Female patients aged 21-40 years or 21-55 years who are using an egg donor.
- • Patients using fresh or frozen ejaculated sperm
- Exclusion Criteria:
- • Previous history of cancer
- • Day 3 embryo transfer
About Vitrolife
Vitrolife is a leading global company dedicated to advancing reproductive medicine and improving outcomes in assisted reproduction. With a strong focus on innovation and quality, Vitrolife develops and provides a comprehensive range of products and services, including culture media, cryopreservation solutions, and laboratory equipment, aimed at enhancing the efficiency and effectiveness of fertility treatments. Committed to supporting healthcare professionals and patients alike, Vitrolife actively engages in clinical research and trials to ensure the continuous improvement of reproductive technologies and to foster successful reproductive outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Frisco, Texas, United States
Goteburg, , Sweden
Malmo, , Sweden
Patients applied
Trial Officials
Thorir Hardarson, PhD
Principal Investigator
Fertilitetscentrum AB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials